Thermo Fisher Scientific CapEx decreased by 19.1% to $376.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.9%, from $362.00M to $376.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -11.8% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $540.00M | $524.00M | $831.00M | $640.00M | $506.00M | $547.00M | $550.00M | $458.00M | $284.00M | $332.00M | $405.00M | $347.00M | $301.00M | $272.00M | $480.00M | $362.00M | $294.00M | $404.00M | $465.00M | $376.00M |
| QoQ Change | — | -3.0% | +58.6% | -23.0% | -20.9% | +8.1% | +0.5% | -16.7% | -38.0% | +16.9% | +22.0% | -14.3% | -13.3% | -9.6% | +76.5% | -24.6% | -18.8% | +37.4% | +15.1% | -19.1% |
| YoY Change | — | — | — | — | -6.3% | +4.4% | -33.8% | -28.4% | -43.9% | -39.3% | -26.4% | -24.2% | +6.0% | -18.1% | +18.5% | +4.3% | -2.3% | +48.5% | -3.1% | +3.9% |